 | • レポートコード：GIR-105X05760 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、デュルバルマブのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。デュルバルマブの種類別市場規模（2.4mL注射、10mL注射）、用途別市場規模（局所進行性尿路上皮がん、転移性尿路上皮がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・デュルバルマブの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Medimmune (AstraZeneca) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：2.4mL注射、10mL注射 ・用途別分析2016年-2026年：局所進行性尿路上皮がん、転移性尿路上皮がん、その他 ・デュルバルマブの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・デュルバルマブのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・デュルバルマブのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・デュルバルマブの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・デュルバルマブの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Durvalumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Durvalumab size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Durvalumab market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Durvalumab market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
2.4mL Injection
10mL Injection
Market segment by Application can be divided into
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other
The key market players for global Durvalumab market are listed below:
Medimmune (AstraZeneca)
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Durvalumab Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Durvalumab Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 2.4mL Injection
1.2.3 10mL Injection
1.3 Market Analysis by Application
1.3.1 Overview: Global Durvalumab Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Locally Advanced Urothelial Carcinoma
1.3.3 Metastatic Urothelial Carcinoma
1.3.4 Other
1.4 Global Durvalumab Market Size & Forecast
1.4.1 Global Durvalumab Sales in Value (2016-2026))
1.4.2 Global Durvalumab Sales in Volume (2016-2026)
1.4.3 Global Durvalumab Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Durvalumab Production Capacity Analysis
1.5.1 Global Durvalumab Total Production Capacity (2016-2026)
1.5.2 Global Durvalumab Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Durvalumab Market Drivers
1.6.2 Durvalumab Market Restraints
1.6.3 Durvalumab Trends Analysis
2 Manufacturers Profiles
2.1 Medimmune (AstraZeneca)
2.1.1 Medimmune (AstraZeneca) Details
2.1.2 Medimmune (AstraZeneca) Major Business
2.1.3 Medimmune (AstraZeneca) Durvalumab Product and Services
2.1.4 Medimmune (AstraZeneca) Durvalumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Durvalumab Sales by Manufacturer
3.1 Global Durvalumab Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Durvalumab Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Durvalumab
3.4 Market Concentration Rate
3.4.1 Top 3 Durvalumab Manufacturer Market Share
3.4.2 Top 6 Durvalumab Manufacturer Market Share
3.5 Global Durvalumab Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Durvalumab Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Durvalumab Market Size by Region
4.1.1 Global Durvalumab Sales in Volume by Region (2016-2026)
4.1.2 Global Durvalumab Revenue by Region (2016-2026)
4.2 North America Durvalumab Revenue (2016-2026)
4.3 Europe Durvalumab Revenue (2016-2026)
4.4 Asia-Pacific Durvalumab Revenue (2016-2026)
4.5 South America Durvalumab Revenue (2016-2026)
4.6 Middle East and Africa Durvalumab Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Durvalumab Sales in Volume by Type (2016-2026)
5.2 Global Durvalumab Revenue by Type (2016-2026)
5.3 Global Durvalumab Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Durvalumab Sales in Volume by Application (2016-2026)
6.2 Global Durvalumab Revenue by Application (2016-2026)
6.3 Global Durvalumab Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Durvalumab Sales by Type (2016-2026)
7.2 North America Durvalumab Sales by Application (2016-2026)
7.3 North America Durvalumab Market Size by Country
7.3.1 North America Durvalumab Sales in Volume by Country (2016-2026)
7.3.2 North America Durvalumab Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Durvalumab Sales by Type (2016-2026)
8.2 Europe Durvalumab Sales by Application (2016-2026)
8.3 Europe Durvalumab Market Size by Country
8.3.1 Europe Durvalumab Sales in Volume by Country (2016-2026)
8.3.2 Europe Durvalumab Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Durvalumab Sales by Type (2016-2026)
9.2 Asia-Pacific Durvalumab Sales by Application (2016-2026)
9.3 Asia-Pacific Durvalumab Market Size by Region
9.3.1 Asia-Pacific Durvalumab Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Durvalumab Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Durvalumab Sales by Type (2016-2026)
10.2 South America Durvalumab Sales by Application (2016-2026)
10.3 South America Durvalumab Market Size by Country
10.3.1 South America Durvalumab Sales in Volume by Country (2016-2026)
10.3.2 South America Durvalumab Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Durvalumab Sales by Type (2016-2026)
11.2 Middle East & Africa Durvalumab Sales by Application (2016-2026)
11.3 Middle East & Africa Durvalumab Market Size by Country
11.3.1 Middle East & Africa Durvalumab Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Durvalumab Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Durvalumab Typical Distributors
12.3 Durvalumab Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Durvalumab Revenue by Type, (USD Million), 2021-2026
Table 2. Global Durvalumab Revenue by Application, (USD Million), 2021-2026
Table 3. Medimmune (AstraZeneca) Basic Information, Manufacturing Base and Competitors
Table 4. Medimmune (AstraZeneca) Major Business
Table 5. Medimmune (AstraZeneca) Durvalumab Product and Services
Table 6. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Global Durvalumab Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 8. Global Durvalumab Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 9. Market Position of Manufacturers in Durvalumab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 10. Global Durvalumab Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 11. Head Office and Durvalumab Production Site of Key Manufacturer
Table 12. Global Durvalumab Sales by Region (2016-2021e) & (K Pcs)
Table 13. Global Durvalumab Sales by Region (2021-2026) & (K Pcs)
Table 14. Global Durvalumab Revenue by Region (2016-2021e) & (USD Million)
Table 15. Global Durvalumab Revenue by Region (2021-2026) & (USD Million)
Table 16. Global Durvalumab Sales by Type (2016-2021e) & (K Pcs)
Table 17. Global Durvalumab Sales by Type (2021-2026) & (K Pcs)
Table 18. Global Durvalumab Revenue by Type (2016-2021e) & (USD Million)
Table 19. Global Durvalumab Revenue by Type (2021-2026) & (USD Million)
Table 20. Global Durvalumab Price by Type (2016-2021e) & (USD/Pcs)
Table 21. Global Durvalumab Price by Type (2021-2026) & (USD/Pcs)
Table 22. Global Durvalumab Sales by Application (2016-2021e) & (K Pcs)
Table 23. Global Durvalumab Sales by Application (2021-2026) & (K Pcs)
Table 24. Global Durvalumab Revenue by Application (2016-2021e) & (USD Million)
Table 25. Global Durvalumab Revenue by Application (2021-2026) & (USD Million)
Table 26. Global Durvalumab Price by Application (2016-2021e) & (USD/Pcs)
Table 27. Global Durvalumab Price by Application (2021-2026) & (USD/Pcs)
Table 28. North America Durvalumab Sales by Country (2016-2021e) & (K Pcs)
Table 29. North America Durvalumab Sales by Country (2021-2026) & (K Pcs)
Table 30. North America Durvalumab Revenue by Country (2016-2021e) & (USD Million)
Table 31. North America Durvalumab Revenue by Country (2021-2026) & (USD Million)
Table 32. North America Durvalumab Sales by Type (2016-2021e) & (K Pcs)
Table 33. North America Durvalumab Sales by Type (2021-2026) & (K Pcs)
Table 34. North America Durvalumab Sales by Application (2016-2021e) & (K Pcs)
Table 35. North America Durvalumab Sales by Application (2021-2026) & (K Pcs)
Table 36. Europe Durvalumab Sales by Country (2016-2021e) & (K Pcs)
Table 37. Europe Durvalumab Sales by Country (2021-2026) & (K Pcs)
Table 38. Europe Durvalumab Revenue by Country (2016-2021e) & (USD Million)
Table 39. Europe Durvalumab Revenue by Country (2021-2026) & (USD Million)
Table 40. Europe Durvalumab Sales by Type (2016-2021e) & (K Pcs)
Table 41. Europe Durvalumab Sales by Type (2021-2026) & (K Pcs)
Table 42. Europe Durvalumab Sales by Application (2016-2021e) & (K Pcs)
Table 43. Europe Durvalumab Sales by Application (2021-2026) & (K Pcs)
Table 44. Asia-Pacific Durvalumab Sales by Region (2016-2021e) & (K Pcs)
Table 45. Asia-Pacific Durvalumab Sales by Region (2021-2026) & (K Pcs)
Table 46. Asia-Pacific Durvalumab Revenue by Region (2016-2021e) & (USD Million)
Table 47. Asia-Pacific Durvalumab Revenue by Region (2021-2026) & (USD Million)
Table 48. Asia-Pacific Durvalumab Sales by Type (2016-2021e) & (K Pcs)
Table 49. Asia-Pacific Durvalumab Sales by Type (2021-2026) & (K Pcs)
Table 50. Asia-Pacific Durvalumab Sales by Application (2016-2021e) & (K Pcs)
Table 51. Asia-Pacific Durvalumab Sales by Application (2021-2026) & (K Pcs)
Table 52. South America Durvalumab Sales by Country (2016-2021e) & (K Pcs)
Table 53. South America Durvalumab Sales by Country (2021-2026) & (K Pcs)
Table 54. South America Durvalumab Revenue by Country (2016-2021e) & (USD Million)
Table 55. South America Durvalumab Revenue by Country (2021-2026) & (USD Million)
Table 56. South America Durvalumab Sales by Type (2016-2021e) & (K Pcs)
Table 57. South America Durvalumab Sales by Type (2021-2026) & (K Pcs)
Table 58. South America Durvalumab Sales by Application (2016-2021e) & (K Pcs)
Table 59. South America Durvalumab Sales by Application (2021-2026) & (K Pcs)
Table 60. Middle East & Africa Durvalumab Sales by Country (2016-2021e) & (K Pcs)
Table 61. Middle East & Africa Durvalumab Sales by Country (2021-2026) & (K Pcs)
Table 62. Middle East & Africa Durvalumab Revenue by Country (2016-2021e) & (USD Million)
Table 63. Middle East & Africa Durvalumab Revenue by Country (2021-2026) & (USD Million)
Table 64. Middle East & Africa Durvalumab Sales by Type (2016-2021e) & (K Pcs)
Table 65. Middle East & Africa Durvalumab Sales by Type (2021-2026) & (K Pcs)
Table 66. Middle East & Africa Durvalumab Sales by Application (2016-2021e) & (K Pcs)
Table 67. Middle East & Africa Durvalumab Sales by Application (2021-2026) & (K Pcs)
Table 68. Direct Channel Pros & Cons
Table 69. Indirect Channel Pros & Cons
Table 70. Durvalumab Typical Distributors
Table 71. Durvalumab Typical Customers
List of Figures
Figure 1. Durvalumab Picture
Figure 2. Global Durvalumab Sales Market Share by Type in 2020
Figure 3. 2.4mL Injection
Figure 4. 10mL Injection
Figure 5. Global Durvalumab Sales Market Share by Application in 2020
Figure 6. Locally Advanced Urothelial Carcinoma
Figure 7. Metastatic Urothelial Carcinoma
Figure 8. Other
Figure 9. Global Durvalumab Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 10. Global Durvalumab Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. United States Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 12. Canada Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Mexico Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Germany Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. France Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. United Kingdom Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Russia Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Italy Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. China Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Japan Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Korea Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. India Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Southeast Asia Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Australia Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Brazil Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Egypt Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Saudi Arabia Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. South Africa Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Turkey Durvalumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Global Durvalumab Sales (2016-2026) & (K Pcs)
Figure 31. Global Durvalumab Production Capacity (2016-2026) & (K Pcs)
Figure 32. Global Durvalumab Production Capacity by Geographic Region: 2020 VS 2021
Figure 33. Durvalumab Market Drivers
Figure 34. Durvalumab Market Restraints
Figure 35. Durvalumab Market Trends
Figure 36. Global Durvalumab Sales Market Share by Manufacturer in 2020
Figure 37. Global Durvalumab Revenue Market Share by Manufacturer in 2020
Figure 38. Durvalumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 39. Top 3 Durvalumab Manufacturer (Revenue) Market Share in 2020
Figure 40. Top 6 Durvalumab Manufacturer (Revenue) Market Share in 2020
Figure 41. Global Durvalumab Sales Market Share by Region (2016-2026)
Figure 42. Global Durvalumab Revenue Market Share by Region (2016-2026)
Figure 43. North America Durvalumab Revenue (2016-2026) & (USD Million)
Figure 44. Europe Durvalumab Revenue (2016-2026) & (USD Million)
Figure 45. Asia-Pacific Durvalumab Revenue (2016-2026) & (USD Million)
Figure 46. South America Durvalumab Revenue (2016-2026) & (USD Million)
Figure 47. Middle East & Africa Durvalumab Revenue (2016-2026) & (USD Million)
Figure 48. Global Durvalumab Sales Market Share by Type (2016-2026)
Figure 49. Global Durvalumab Revenue Market Share by Type (2016-2026)
Figure 50. Global Durvalumab Price by Type (2016-2026) & (USD/Pcs)
Figure 51. Global Durvalumab Sales Market Share by Application (2016-2026)
Figure 52. Global Durvalumab Revenue Market Share by Application (2016-2026)
Figure 53. Global Durvalumab Price by Application (2016-2026) & (USD/Pcs)
Figure 54. North America Durvalumab Sales Market Share by Country (2016-2026)
Figure 55. North America Durvalumab Revenue Market Share by Country (2016-2026)
Figure 56. North America Durvalumab Sales Market Share by Type (2016-2026)
Figure 57. North America Durvalumab Sales Market Share by Application (2016-2026)
Figure 58. Europe Durvalumab Sales Market Share by Country (2016-2026)
Figure 59. Europe Durvalumab Revenue Market Share by Country (2016-2026)
Figure 60. Europe Durvalumab Sales Market Share by Type (2016-2026)
Figure 61. Europe Durvalumab Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Durvalumab Sales Market Share by Region (2016-2026)
Figure 63. Asia-Pacific Durvalumab Revenue Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Durvalumab Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Durvalumab Sales Market Share by Application (2016-2026)
Figure 66. South America Durvalumab Sales Market Share by Country (2016-2026)
Figure 67. South America Durvalumab Revenue Market Share by Country (2016-2026)
Figure 68. South America Durvalumab Sales Market Share by Type (2016-2026)
Figure 69. South America Durvalumab Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Durvalumab Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Durvalumab Revenue Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Durvalumab Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Durvalumab Sales Market Share by Application (2016-2026)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
Figure 75. Methodology
Figure 76. Research Process and Data Source
尿路上皮癌診断の世界市場2018-2025 Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis.The increasing trends of cigarette smoking is increasing the chances of urothelial carcinoma manifold. The Urothelial Carcinoma Diagnostics marke…- 肝細胞がん治療薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAV…
- 世界のアテゾリズマブ市場 2021：企業別、地域別、種類・用途別 The Atezolizumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recen…
- 髄腔内バッファー電解質/デキストロース注入の世界市場2018-2025 buffered intrathecal electrolyte/dextrose injection is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.In 2018, the global Buffered Intrathecal Electrolyte/Dextrose Injection…
- 髄腔内バッファー電解質/デキストロース注入薬の世界市場2018-2025 buffered intrathecal electrolyte/dextrose injection is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.In 2018, the global Buffered Intrathecal Electrolyte/Dextrose Injection…